Cytos completes major financing

Wednesday 16 May 2012

Cytos Biotechnolgy AG has completed a major portion of a planned CHF 37 million (€30.8 million) equity and debt financing that will give it the resources to conduct a global, multi-centre Phase 2b study of its lead asthma product, CYT003.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland